
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Summary
Aclaris Therapeutics stock fell following the release of disappointing results from a mid-stage skin disease trial. Despite missing the main study goals, company leadership stated that development priorities and future timelines for key drug programs remain unchanged.
Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study. Walker emphasized that Aclaris remains committed to advancing its oral kinase inhibitors and bispecific antibody programs toward major clinical and regulatory milestones throughout 2027. Bosakitug Misses…
Source: Read the full story at Top Stories Feed